• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

转移性三阴性乳腺癌长期生存病例报告:转移性疾病的治疗可能性

Case report of long-term survival with metastatic triple-negative breast carcinoma: Treatment possibilities for metastatic disease.

作者信息

Chue Ben Man-Fai, La Course Bryce Douglas

机构信息

Lifespring Cancer Treatment Center, Seattle, WA.

出版信息

Medicine (Baltimore). 2019 Apr;98(16):e15302. doi: 10.1097/MD.0000000000015302.

DOI:10.1097/MD.0000000000015302
PMID:31008982
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC6494386/
Abstract

RATIONALE

Breast cancer is the most common as well as one of the most devastating cancers among women in the United States. Prognosis is poor for patients with metastatic breast cancer, especially for patients with so-called "triple-negative" disease. The lack of effective therapies for metastatic triple-negative breast cancer outlines the need for novel and innovative treatment strategies.

PATIENT CONCERNS

A 58-year-old underwent a mastectomy which revealed a recurrent triple-negative breast carcinoma. Afterward, she presented with a growing mass in her left axilla and chest wall. A computed tomography scan showed axillary and supraclavicular adenopathy, nodules in the left upper and lower lobe of the lungs, and 2 areas of disease in the liver. A bone scan showed lesions in the ribs.

DIAGNOSIS

The patient was diagnosed with a recurrent metastatic triple-negative breast carcinoma that spread to the lung, liver, and bones.

INTERVENTIONS

The patient was treated with metronomic chemotherapy, sequential chemotherapy regimens, and immunotherapy.

OUTCOMES

The patient is now over 15 years out from her diagnosis of metastatic disease without any evidence of recurrent disease, likely due to the patient's treatment strategy which included sequential metronomic chemotherapy regimens and immunotherapy.

LESSONS

Sequential metronomic chemotherapy regimens in combination with immunotherapy might be an effective treatment option for patients with metastatic triple-negative breast cancer. We hope that this case can provide some guidance for the treatment of metastatic triple-negative breast cancer and motivate research that can potentially lead to more cases of long-term survival for patients who develop this dismal disease.

摘要

理论依据

乳腺癌是美国女性中最常见且最具毁灭性的癌症之一。转移性乳腺癌患者的预后较差,尤其是所谓的“三阴性”疾病患者。转移性三阴性乳腺癌缺乏有效的治疗方法,这凸显了对新颖创新治疗策略的需求。

患者情况

一名58岁女性接受了乳房切除术,结果显示为复发性三阴性乳腺癌。之后,她左腋窝和胸壁出现肿块且不断增大。计算机断层扫描显示腋窝和锁骨上淋巴结肿大、左肺上下叶有结节以及肝脏有2处病灶。骨扫描显示肋骨有病变。

诊断

患者被诊断为复发性转移性三阴性乳腺癌,已扩散至肺、肝和骨。

干预措施

患者接受了节拍化疗、序贯化疗方案和免疫治疗。

结果

自诊断为转移性疾病以来,患者已超过15年,且无任何复发疾病迹象,这可能得益于患者的治疗策略,包括序贯节拍化疗方案和免疫治疗。

经验教训

序贯节拍化疗方案联合免疫治疗可能是转移性三阴性乳腺癌患者的一种有效治疗选择。我们希望这个病例能为转移性三阴性乳腺癌的治疗提供一些指导,并推动相关研究以可能为罹患这种严重疾病的患者带来更多长期生存的案例。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/8e80/6494386/149641814558/medi-98-e15302-g001.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/8e80/6494386/149641814558/medi-98-e15302-g001.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/8e80/6494386/149641814558/medi-98-e15302-g001.jpg

相似文献

1
Case report of long-term survival with metastatic triple-negative breast carcinoma: Treatment possibilities for metastatic disease.转移性三阴性乳腺癌长期生存病例报告:转移性疾病的治疗可能性
Medicine (Baltimore). 2019 Apr;98(16):e15302. doi: 10.1097/MD.0000000000015302.
2
Can we cure stage IV triple-negative breast carcinoma?: Another case report of long-term survival (7 years).我们能治愈IV期三阴性乳腺癌吗?:另一例长期生存(7年)的病例报告。
Medicine (Baltimore). 2019 Sep;98(38):e17251. doi: 10.1097/MD.0000000000017251.
3
Long-term complete response in a patient with liver metastases from breast cancer treated with metronomic chemotherapy.接受节拍化疗治疗的乳腺癌肝转移患者的长期完全缓解。
Tumori. 2014 May-Jun;100(3):e79-82. doi: 10.1700/1578.17238.
4
Beyond Axillary Lymph Node Metastasis, BMI and Menopausal Status Are Prognostic Determinants for Triple-Negative Breast Cancer Treated by Neoadjuvant Chemotherapy.除腋窝淋巴结转移外,体重指数和绝经状态是新辅助化疗治疗三阴性乳腺癌的预后决定因素。
PLoS One. 2015 Dec 18;10(12):e0144359. doi: 10.1371/journal.pone.0144359. eCollection 2015.
5
Capecitabine metronomic chemotherapy combined with autologous CIK cell immunotherapy in the treatment of recurrent and metastatic triple-negative breast cancer.卡培他滨节拍化疗联合自体 CIK 细胞免疫治疗复发性转移性三阴性乳腺癌。
J BUON. 2021 May-Jun;26(3):734-740.
6
[Treatment outcomes and clinicopathologic characteristics of advanced triple-negative breast cancer patients].[晚期三阴性乳腺癌患者的治疗结果及临床病理特征]
Zhonghua Zhong Liu Za Zhi. 2011 May;33(5):381-4.
7
Primary and secondary distant metastatic breast cancer: two sides of the same coin.原发和继发远处转移性乳腺癌:一枚硬币的两面。
Breast. 2014 Feb;23(1):26-32. doi: 10.1016/j.breast.2013.10.007. Epub 2013 Nov 8.
8
[A case of locally advanced and metastatic breast cancer successfully treated with combination therapy of paclitaxel and bevacizumab].[一例局部晚期转移性乳腺癌经紫杉醇与贝伐单抗联合治疗成功治愈]
Gan To Kagaku Ryoho. 2014 Aug;41(8):1027-9.
9
[Long-Term Survival of a Patient with Triple-Negative Breast Cancer with Hormone Receptor Status Conversion between Primary and Metastatic Tumors].[三阴性乳腺癌患者原发肿瘤与转移瘤之间激素受体状态转换后的长期生存情况]
Gan To Kagaku Ryoho. 2022 Jun;49(6):697-699.
10
Prognosis of selected triple negative apocrine breast cancer patients who did not receive adjuvant chemotherapy.未接受辅助化疗的特定三阴性大汗腺癌患者的预后。
Breast. 2020 Oct;53:138-142. doi: 10.1016/j.breast.2020.07.003. Epub 2020 Jul 24.

引用本文的文献

1
Metronomic chemotherapy and drug repurposing: A paradigm shift in oncology.节拍化疗与药物重新利用:肿瘤学中的范式转变。
Heliyon. 2024 Jan 14;10(3):e24670. doi: 10.1016/j.heliyon.2024.e24670. eCollection 2024 Feb 15.
2
Thymoquinone Inhibition of Chemokines in TNF-α-Induced Inflammatory and Metastatic Effects in Triple-Negative Breast Cancer Cells.姜黄素抑制 TNF-α诱导的三阴性乳腺癌细胞中趋化因子的炎症和转移作用。
Int J Mol Sci. 2023 Jun 8;24(12):9878. doi: 10.3390/ijms24129878.
3
Hedgehog Signaling Regulates Treg to Th17 Conversion Through Metabolic Rewiring in Breast Cancer.

本文引用的文献

1
Cancer statistics, 2018.癌症统计数据,2018 年。
CA Cancer J Clin. 2018 Jan;68(1):7-30. doi: 10.3322/caac.21442. Epub 2018 Jan 4.
2
Tumor-Infiltrating Lymphocytes in Triple Negative Breast Cancer: The Future of Immune Targeting.三阴性乳腺癌中的肿瘤浸润淋巴细胞:免疫靶向治疗的未来
Clin Med Insights Oncol. 2016 Apr 5;10(Suppl 1):31-9. doi: 10.4137/CMO.S34540. eCollection 2016.
3
Metronomic chemotherapy from rationale to clinical studies: a dream or reality?节拍化疗:从理论依据到临床研究,是梦想还是现实?
刺猬信号通过代谢重编程调节乳腺癌中 Treg 向 Th17 的转化。
Cancer Immunol Res. 2023 May 3;11(5):687-702. doi: 10.1158/2326-6066.CIR-22-0426.
4
A survey of open questions in adaptive therapy: Bridging mathematics and clinical translation.适应性治疗中的开放性问题研究:弥合数学与临床转化的桥梁。
Elife. 2023 Mar 23;12:e84263. doi: 10.7554/eLife.84263.
5
(Forssk.) Sch.Bip Flower Dichloromethane Extract Exerts Anti-Proliferative and Pro-Apoptotic Properties in Human Triple-Negative Breast Cancer (MDA-MB-231) Cells: In Vitro and In Silico Studies.(福斯克)施密特氏双花二氯甲烷提取物对人三阴性乳腺癌(MDA-MB-231)细胞具有抗增殖和促凋亡特性:体外和计算机模拟研究
Pharmaceuticals (Basel). 2022 Aug 26;15(9):1060. doi: 10.3390/ph15091060.
6
Current Research Status of Metronomic Chemotherapy in Combination Treatment of Breast Cancer.节拍化疗联合治疗乳腺癌的研究现状。
Oncol Res Treat. 2022;45(11):681-692. doi: 10.1159/000526481. Epub 2022 Aug 19.
7
An Integrated In Silico, In Vitro and Tumor Tissues Study Identified Selenoprotein S (SELENOS) and Valosin-Containing Protein (VCP/p97) as Novel Potential Associated Prognostic Biomarkers in Triple Negative Breast Cancer.一项整合计算机模拟、体外实验和肿瘤组织的研究确定了硒蛋白S(SELENOS)和含缬酪肽蛋白(VCP/p97)作为三阴性乳腺癌新的潜在相关预后生物标志物。
Cancers (Basel). 2022 Jan 27;14(3):646. doi: 10.3390/cancers14030646.
8
Correlation of Clinicopathological Features of Breast Cancer with Molecular Subtypes Taking Ki-67 into Consideration: Single Institution Experience Over 5 Years.考虑Ki-67的乳腺癌临床病理特征与分子亚型的相关性:单机构5年经验
Curr Health Sci J. 2021 Jul-Sep;47(3):348-352. doi: 10.12865/CHSJ.47.03.03. Epub 2021 Sep 30.
9
Can we cure stage IV triple-negative breast carcinoma?: Another case report of long-term survival (7 years).我们能治愈IV期三阴性乳腺癌吗?:另一例长期生存(7年)的病例报告。
Medicine (Baltimore). 2019 Sep;98(38):e17251. doi: 10.1097/MD.0000000000017251.
Crit Rev Oncol Hematol. 2015 Jul;95(1):46-61. doi: 10.1016/j.critrevonc.2015.01.008. Epub 2015 Jan 20.
4
Metronomic chemotherapy: an attractive alternative to maximum tolerated dose therapy that can activate anti-tumor immunity and minimize therapeutic resistance.节拍化疗:一种有吸引力的替代最大耐受剂量疗法的方法,它可以激活抗肿瘤免疫并使治疗耐药性最小化。
Cancer Lett. 2015 Mar 28;358(2):100-106. doi: 10.1016/j.canlet.2014.12.039. Epub 2014 Dec 23.
5
New insights into metronomic chemotherapy-induced immunoregulation.关于节拍化疗诱导免疫调节的新见解。
Cancer Lett. 2014 Nov 28;354(2):220-6. doi: 10.1016/j.canlet.2014.08.028. Epub 2014 Aug 25.
6
Platinum-based chemotherapy in triple-negative advanced breast cancer.三阴性晚期乳腺癌的铂类化疗
Breast Cancer Res Treat. 2014 Aug;146(3):567-72. doi: 10.1007/s10549-014-3033-4. Epub 2014 Jul 8.
7
The pharmacological bases of the antiangiogenic activity of paclitaxel.紫杉醇抗血管生成活性的药理学基础。
Angiogenesis. 2013 Jul;16(3):481-92. doi: 10.1007/s10456-013-9334-0. Epub 2013 Feb 7.
8
Comparison of safety and toxicity of liposomal doxorubicin vs. conventional anthracyclines: a meta-analysis.脂质体多柔比星与传统蒽环类药物安全性和毒性的比较:一项荟萃分析。
Exp Hematol Oncol. 2012 Apr 23;1(1):10. doi: 10.1186/2162-3619-1-10.
9
Immunomodulatory effects of low dose chemotherapy and perspectives of its combination with immunotherapy.低剂量化疗的免疫调节作用及其与免疫疗法联合应用的前景。
Int J Cancer. 2013 Jun 1;132(11):2471-8. doi: 10.1002/ijc.27801. Epub 2012 Sep 21.
10
Topical TLR7 agonist imiquimod can induce immune-mediated rejection of skin metastases in patients with breast cancer.局部 TLR7 激动剂咪喹莫特可诱导乳腺癌皮肤转移患者的免疫介导排斥反应。
Clin Cancer Res. 2012 Dec 15;18(24):6748-57. doi: 10.1158/1078-0432.CCR-12-1149. Epub 2012 Jul 5.